Cancer diagnostics company Biomoda has completed patient enrollment and sample collection for the pilot study to determine the clinical sensitivity and specificity of its CyPath diagnostic assay for the early detection of lung cancer.
The pilot study involved two groups: the first group included a high-risk group of military veterans who smoked more than 20 pack years, while the second group included patients diagnosed with lung cancer who have not started treatment.
CyPath labeling solution works by binding to cancer cells and causing them to fluoresce under specific frequencies of light.
Biomoda is seeking approval from the US Food and Drug Administration for its diagnostic technology as a Class III medical device.